CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Context Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.24−0.01 (-2.30%)
Close on Oct 19, 2026
- Market cap
- $22.69M
- P/E (TTM)
- –
- Dividend yield
- –
Context Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Market Cap | $21.90M | $164.85M |
| Enterprise Value | -$21.09M | $87.06M |
| PB Ratio | 0.57 | 2.03 |
| P/TBV Ratio | 0.57 | 2.31 |
Income (trailing twelve months)
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$48.73M | -$21.44M |
| Net Income | -$45.96M | -$22.46M |
| EBITDA | -$48.71M | -$16.91M |
| EPS (Diluted) | -$0.48 | -$0.83 |
Returns
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -76.1% | -53.1% |
| Return on Assets (ROA) | -69.0% | -41.0% |
| Return on Capital Employed (ROCE) | -127.4% | -37.8% |
Balance sheet
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $42.99M | $62.42M |
| Net Cash (Debt) | $42.99M | $15.68M |
| Net Cash Per Share | $0.47 | $0.66 |
| Equity (Book Value) | $38.17M | $48.79M |
| Book Value Per Share | $0.42 | $1.36 |
| Tangible Book Value | $38.17M | $23.06M |
| Working Capital | $37.93M | $75.77M |
Financial position
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 5.81 | 3.30 |
| Quick Ratio | 5.45 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$33.97M | -$12.35M |
| Capital Expenditures | -$55.75K | -$1.06M |
| Free Cash Flow | -$34.03M | -$20.28M |
| FCF Per Share | -$0.37 | -$0.42 |
Efficiency
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$3.06M | -$703.34K |
| Employee Count | 15 | 74 |
Dividends and yields
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -209.8% | -22.7% |
| FCF Yield | -155.3% | -9.07% |
| Buyback Yield | -0.07% | -0.73% |
| Shareholder Yield | -0.07% | 0.00% |
Shares
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 91,879,200 | 58,179,650 |
| Shares Change (YoY) | 7.92% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 90,117,900 | 49,173,100 |
| Shares Held by Insiders | 1.92% | 11.6% |
| Shares Held by Institutions | 68.4% | 59.4% |
Scores
| Measure | Context Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -5.53 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Context Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.